NASDAQ:BNTC - BENITEC BIOPHAR/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.95 -0.05 (-2.50 %) (As of 03/24/2019 04:00 PM ET)Previous Close$1.95Today's Range$1.95 - $1.9552-Week Range$1.01 - $4.90Volume100 shsAverage Volume8,093 shsMarket Capitalization$21.51 millionP/E RatioN/ADividend YieldN/ABeta2.64 ProfileDiscussionAnalyst RatingsChartDividendEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology related to head and neck squamous cell carcinoma. The company was founded in 1995 and is headquartered in North Sydney, Australia. Receive BNTC News and Ratings via Email Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BNTC Previous Symbol CUSIPN/A CIKN/A Webwww.benitec.com Phone61-2-9555-6986Debt Debt-to-Equity RatioN/A Current Ratio13.96 Quick Ratio8.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.65 million Price / Sales5.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book1.48Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-9,020,000.00 Net Margins-247.57% Return on Equity-69.46% Return on Assets-62.13%Miscellaneous EmployeesN/A Outstanding Shares11,030,000Market Cap$21.51 million Next Earnings Date3/28/2019 (Estimated) OptionableNot Optionable BENITEC BIOPHAR/S (NASDAQ:BNTC) Frequently Asked Questions What is BENITEC BIOPHAR/S's stock symbol? BENITEC BIOPHAR/S trades on the NASDAQ under the ticker symbol "BNTC." How often does BENITEC BIOPHAR/S pay dividends? What is the dividend yield for BENITEC BIOPHAR/S? BENITEC BIOPHAR/S declared a ... dividend on Monday, May 28th. Stockholders of record on Monday, June 4th will be paid a dividend of $0.0029 per share on Friday, June 8th. The ex-dividend date of this dividend is Friday, June 1st. View BENITEC BIOPHAR/S's Dividend History. When is BENITEC BIOPHAR/S's next earnings date? BENITEC BIOPHAR/S is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for BENITEC BIOPHAR/S. Has BENITEC BIOPHAR/S been receiving favorable news coverage? News articles about BNTC stock have trended neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BENITEC BIOPHAR/S earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the immediate future. Who are some of BENITEC BIOPHAR/S's key competitors? Some companies that are related to BENITEC BIOPHAR/S include Sunesis Pharmaceuticals (SNSS), Otonomy (OTIC), Pharmaxis (PXSLY), Catabasis Pharmaceuticals (CATB), Acasti Pharma (ACST), AVEO Pharmaceuticals (AVEO), vTv Therapeutics (VTVT), SCYNEXIS (SCYX), Elite Pharmaceuticals (ELTP), Sienna Biopharmaceuticals (SNNA), Tiziana Life Sciences (TLSA), Alimera Sciences (ALIM), Ovid Therapeutics (OVID), Apricus Biosciences (APRI) and Medicure (MCUJF). What other stocks do shareholders of BENITEC BIOPHAR/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other BENITEC BIOPHAR/S investors own include Amarin (AMRN), BIOLINERX LTD/S (BLRX), Neurocrine Biosciences (NBIX), Arena Pharmaceuticals (ARNA), Nightstar Therapeutics (NITE), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), Neovasc (NVCN), Gilead Sciences (GILD) and Allergan (AGN). Who are BENITEC BIOPHAR/S's key executives? BENITEC BIOPHAR/S's management team includes the folowing people: Dr. Jerel A. Banks, CEO & Exec. ChairmanMs. Georgina Kilfoil, Chief Devel. Officer (Age 50)Ms. Megan Joan Boston, Exec. Director & Head of Operations - AustraliaMr. Bryan Dulhunty, Chief Financial OfficerDr. Michael Graham, Head of Discovery & Founding Scientist When did BENITEC BIOPHAR/S IPO? (BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager. How do I buy shares of BENITEC BIOPHAR/S? Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BENITEC BIOPHAR/S's stock price today? One share of BNTC stock can currently be purchased for approximately $1.95. How big of a company is BENITEC BIOPHAR/S? BENITEC BIOPHAR/S has a market capitalization of $21.51 million and generates $3.65 million in revenue each year. What is BENITEC BIOPHAR/S's official website? The official website for BENITEC BIOPHAR/S is http://www.benitec.com. How can I contact BENITEC BIOPHAR/S? BENITEC BIOPHAR/S's mailing address is 99 Mount Street Suite 1201, Sydney C3, 2060. The biotechnology company can be reached via phone at 61-2-9555-6986 or via email at [email protected] MarketBeat Community Rating for BENITEC BIOPHAR/S (NASDAQ BNTC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 133 (Vote Outperform)Underperform Votes: 145 (Vote Underperform)Total Votes: 278MarketBeat's community ratings are surveys of what our community members think about BENITEC BIOPHAR/S and other stocks. Vote "Outperform" if you believe BNTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNTC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: What Does a Sell-Side Analyst Rating Mean?